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The need to transfer human biological materials (HBMs) across 
national boundaries has become increasingly important in the light 
of increased biobank and commercial activities globally. Biobank 
research provides for significant and accelerated improvements in the 
understanding of health, diseases, and the effectiveness, efficiency, safety 
and quality of preventive, diagnostic and therapeutic interventions. [1] 
In view of South Africa (SA)’s history of colonisation and racial 
discrimination, coupled with well-known instances of exploitation 
of research participants in the developing world, it is critical that the 
management of HBMs from and to other jurisdictions is cautiously 
scrutinised and regulated. A generally accepted way in which this can 
be achieved is with the systematic use of material transfer agreements 
(MTAs). While in SA HBMs are governed by chapter 8 of the National 
Health Act 61 of 2003 (NHA),[2] there are no regulations governing 
biobanks and the cross-border transfer of HBMs, except for those 
relating to applications for import and export permits.[3]
The purpose of MTAs is to facilitate the exchange of HBMs and 
associated data between researchers/institutions, as well as to safeguard 
the interests of research participants, researchers and their institutions. 
Conventionally, an MTA typically sets out the uses of the material, the 
quality of the material, terms and conditions under which the material 
may be used, third-party transfers, benefit-sharing mechanisms, and 
intellectual property rights and other legal and/or regulatory policies or 
guidelines that need to be considered.[4] In SA, the Health Professions 
Council of South Africa[5] and the National Department of Health 
guidelines on Ethics in Health Research (National Ethical Guidelines) [6] 
require the conclusion of MTAs before HBMs are transferred out 
of SA. The National Ethical Guidelines (section 3.5.2.3) in addition 
state that ‘where data or materials are shared with researchers in 
other institutions, the recipient institution should agree to comply 
with the requirements of the donor institution’, as well as with ‘any 
additional requirements of the recipient institution’. The National 
Ethical Guidelines recommend that these inter-institutional sharing 
agreements are confirmed in writing.
The purpose of this article is to explore the need for a uniform 
MTA in SA and to discuss some aspects of the recently gazetted 
national MTA.[7] The point of the article is not to address complex 
legal and philosophical debates relating to the transfer of HBMs, but 
to provide a factual analysis of the current situation with regard to 
HBMs in SA.
Why a need for MTAs?
Research using HBMs should have societal benefits and contribute 
to public health objectives.[1] It was common practice for researchers 
to share research materials freely, as scientific research relies, inter 
alia, on the ability of researchers to replicate and test published 
research results. In the context of health research, such an exercise 
would require access to the relevant biological material and/or 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Protecting participants in health research:  
The South African Material Transfer Agreement
M Labuschaigne,1 BA (cum laude), BA Hons (cum laude), MA (cum laude), DLitt, LLB (cum laude), LLD;  
A Dhai,2 MB ChB, FCOG, LLM, PG Dip (Int Res Ethics), PhD; S Mahomed,1 BCom, LLB, LLM, PhD; K Behrens,2 BA, MA, D Litt et Phil;  
A Nienaber,3 BA Hons, LLB, LLM (cum laude), LLD; K Moodley,4 MB ChB, MFamMed (cum laude), MPhil (Applied Ethics) (cum laude),  
FCFP (SA), DPhil, Executive MBA; P Cleaton-Jones,2 MB BCh, PhD, DSc (Dent); A Olckers,5 NDip Med Tech, BSc, MSc, PhD;  
N Maepa,6 BA Law, LLB, LLM; C Penny,7 BSc Hons, PhD
1 Department of Jurisprudence, School of Law, University of South Africa, Pretoria, South Africa
2 Steve Biko Centre for Bioethics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
3  Department of Public Law, Faculty of Law, University of Pretoria, South Africa; and Faculty of Health Sciences Research Ethics Committee, 
University of Pretoria, South Africa
4  Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,  
South Africa
5 DNAbiotec (Pty) Ltd, Pretoria, South Africa
6 Legal Office, University of the Witwatersrand, Johannesburg, South Africa
7  Human Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South Africa; and Department of Internal 
Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Corresponding author: M Labuschaigne (slabbmn@unisa.ac.za)
The need to transfer human biological materials (HBMs) across national boundaries has become increasingly important in view of increased 
biobank and commercial activities globally. In light of South Africa (SA)’s history of colonisation and racial discrimination, coupled with 
well-known instances of exploitation of research participants in the developing world, it is critical that the management of HBMs from and 
to other jurisdictions is explored and regulated. Material transfer agreements (MTAs) represent an important point of departure in such a 
process. This article explores the need for a uniform MTA in SA and discusses some aspects of the recently gazetted national MTA, which 
provides a framework that can serve as a safeguard for cross-border transfer of HBMs in the absence of the National Health Act’s chapter 
8 regulations in this regard.
S Afr Med J 2019;109(5):353-356. DOI:10.7196/SAMJ.2019.v109i5.13803
354       May 2019, Vol. 109, No. 5
RESEARCH
information derived therefrom. The increasing gap between basic 
research and commercial developments has led to more pronounced 
efforts to capitalise on novel research leading to, among others, new 
commercially viable genes, cell lines, reagents or antibodies, which 
in turn rely on access to HBMs and associated data. Genome and 
genetic resources are specifically targeted for public and private 
investment funding to enable further discovery of gene regulation 
or function. However, vexing questions have emerged, e.g. who 
will own or control these downstream discoveries,[8] the type of 
consent for secondary use of HBMs, who will share the benefits 
resulting from these studies, how disputes are to be resolved should 
they arise, and the power imbalances in international collaborative 
research. In addition, the reality is that exploitation of research 
participants/donors in health research in SA does occur. Empirical 
evidence has confirmed that HBMs were leaving the country without 
export permits and MTAs during international collaborative research 
in both investigator-initiated and industry-driven clinical trials.[9] 
Furthermore, the African context needs to be understood, including 
the fact that deep significance is attached to blood and HBMs by 
black African communities.[10,11] Despite these concerns, MTAs that 
have standardly been used in SA so far have typically lacked ethical 
safeguards, do not address concerns specific to SA,[12] and have 
restricted protections in that they derive from strict legal principles 
only. This is not sufficient for SA settings. The evidence demonstrates 
that more needs to be done in order to effectively protect local 
donors and institutions when the cross-border transfer of HBMs 
is contemplated.[9,10,11,13] Furthermore, the Protection of Personal 
Information Act 4 of 2013 (POPI)[14] explicitly states that personal 
information may only be transferred to a foreign country if that 
country offers similar protections in respect of personal information 
and the transfers thereof, as envisaged by the Act. Currently no 
uniformity or standardisation exists as each institution chooses to 
utilise its own/sponsor-preferred MTA. For over a decade there have 
been calls by concerned parties, including meetings attended by 
some of the authors of this article and convened by the Department 
of Science and Technology, for a uniform MTA for SA that takes into 
consideration our ethical and sociocultural context.
Universities in SA are under increasing pressure to generate income 
from sources other than government subsidies. Many research 
institutions have technology transfer or research offices specifically 
dedicated to managing research grant applications and related matters. 
Applications for ethical clearance are routinely reviewed by health 
research ethics committees (HRECs) at these institutions. Researchers 
and students generally lack the relevant legal knowledge to enter into 
legal agreements and complete research ethics applications without 
assistance from either an HREC, a relevant technology transfer office 
(TTO) or a research office. This centralisation of contract services 
in a technology transfer or research services office is often criticised 
for leading to delays and conflicts between the interests of research 
participants, researchers and their institutions.[15] Moreover, research 
offices or TTOs may struggle to balance conflicting mandates, e.g. to 
commercialise research at their institutions to achieve financial returns 
on investments and to promote the desired community-level sharing of 
materials, data[16] and benefits.
The SA National MTA
In July 2018, the National Department of Health gazetted a Material 
Transfer Agreement of Human Biological Materials (SA MTA)[7] 
for use in research or clinical trials under the auspices of HRECs as 
regulated by the NHA. The SA MTA is founded on the principles of 
justice, fairness and dignity, in line with the principles of the World 
Medical Association’s Declaration of Taipei on Ethical Considerations 
Regarding Health Databases and Biobanks[1] and the Council for 
International Association of Medical Scientists guidelines,[17] and in 
keeping with international best practices. Some aspects of the MTA 
are discussed below.
The SA MTA as a framework
The SA MTA[7] is applicable when materials (HBMs and data) are 
transferred outside SA for health research purposes, which includes 
biobank research. The objective of the MTA is to set out a framework/
template within which the parties engage in the transfer, use and 
other processing of the materials. This means that the SA MTA 
provides guidance on specific ethicolegal principles that must be 
respected when cross-border transfer takes place. While the cover 
page to the SA MTA indicates that ‘All the providers and recipients 
of the biological material for use in research or clinical trials under 
the auspices of the Health Research Ethics Committees shall use the 
Materials Transfer Agreement of human Biological Materials [sic]’, 
clause 1 of the SA MTA explicitly states that the ‘objective of this 
Agreement is to set out a framework within which the Parties will 
engage in the transfer, use and other processing of the Materials  ...’. 
The intention of the SA MTA is therefore not to prescribe its use 
verbatim, but rather to serve as a uniform, national template.
Parties to the SA MTA and the role of the HREC
The SA MTA refers to an HREC (required by law to be registered 
with the SA National Health Research Ethics Council in terms of 
section 73 of the NHA), the Providing Institution (provider) and the 
Recipient Institution (recipient), as parties to the agreement.
It may be argued that the HREC is not a separate legal entity 
and hence is unable to enter into such an agreement. The question 
whether HRECs should be part of such agreements is best addressed 
by referring to the HREC’s role and responsibility with regard to the 
review and approval of research protocols that require the transfer 
of HBMs. Firstly, HRECs are ideally situated within research institu-
tions to provide the required oversight to ensure that the ethicolegal 
requirements of MTAs are complied with and adequately monitored, 
while also making sure that scientific progress is not stifled. Moreover, 
although there is no general legal duty of care recognised in SA,[18,19] 
except when there is a special relationship between the duty-bearer and 
another person, such as doctor v. patient, parent v. child, teacher v. pupil 
or police officer v. citizen, such a special relationship exists between an 
HREC and a research participant.[20] One of the main purposes of an 
HREC is to ensure that adequate protections are in place for research 
participants when health research is contemplated. Inversely and by 
analogy, it may be argued that an HREC owes research participants a 
reasonable duty of care and may hence be held liable for harm resulting 
to research participants through negligently conducted research, if 
such a committee failed to take the necessary reasonable steps to 
prevent reasonably foreseeable harm or injury to research participants. 
In the Canadian Supreme Court judgment of  Weiss  v.  Solomon,[21] 
the family of a research participant who suffered a cardiac arrest and 
died subsequent to an angiogram as part of a research study sued the 
principal investigator, the hospital and a physician who referred the 
deceased to the study. The court held the primary investigator and 
hospital liable. The liability against the hospital was based, in part, 
on the fact that the HREC of the hospital had approved the research 
protocol and the consent form that the court found to be deficient. 
An institution that has established an HREC will be vicariously liable 
for negligent conduct by its HRECs with regard to ethical reviews that 
caused foreseeable harm to a participant.[20]
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SA, too, has seen litigation where the HREC is mentioned in 
proceedings after granting ethics approval to a pharmaceutical 
research project. In Venter v Roche Products (Pty) Ltd,[22] a full bench 
of the Western Cape High Court considered whether the plaintiff, 
Mr Venter, was entitled to compensation for non-medical costs such 
as pain and suffering, loss of income and general damages, even 
though the HREC-reviewed informed consent document specifically 
excluded such claims. In this case, the High Court clearly placed 
responsibility for protecting the interests of research participants 
(such as whether and to what extent they receive compensation and 
whether this was in the participant informed consent documentation) 
squarely on the shoulders of the HREC: the HREC grants ethics 
approval in terms of section 73(2)(b) to ‘protocol[s] [that] meet 
the ethical standards of that health research ethics committee’. It is 
possible to deduce that in the same way compensation for research-
related injuries was regarded by the court as an ethical issue, so too in 
the future the existence and contents of an MTA will be regarded by 
the courts as ethically relevant. Therefore, HRECs will have to ensure 
that MTAs are in place and that they conform to the norms and 
standards set out in the NHA and the National Ethical Guidelines.
The HREC is directly involved in reviewing protocols, and is 
closest in proximity to the material transfer process (clause 6). The 
SA MTA[7] (clause 6) includes provisions that speak directly to 
the ethical safeguards for HBMs and data, and HREC oversight is 
emphasised throughout the document. The HREC often becomes 
involved in negotiating and resolving disputes as a first point of 
reference for ethical concerns that may arise. It is to be noted that 
the Draft R&D Blueprint MTA developed by the WHO for severe 
emergency disease with potential to create a public health emergency 
indicates that ‘in some cases it may be desirable to include a suitable 
third party in MTAs to act as a neutral party to ensure negotiation 
in good faith and an unbiased implementation’.[23] An HREC should 
have no vested interest in the research process. It acts to protect and 
balance the interests of research participants and local researchers 
with scientific research pursuits, and hence it is submitted that it is 
well placed to sign off on the MTA.
Custodianship and ownership
The SA MTA[7] (clause 3.3) stipulates that the providing institute 
is custodian of the materials. The concept of custodianship has 
been supported where HBMs are concerned.[24-26] There have 
been incidents in the past where disputes arose between local 
researchers and institutions outside SA where these institutions 
claimed ownership of the materials and associated data after transfer 
took place, resulting in local researchers being unable to access the 
materials.[27] In addition, there have been several recorded disputes 
with regard to ownership of HBMs outside SA.[28-36] Allowing the 
providing institute to remain custodian of the materials allows for the 
caretaking obligation for materials, as well as the obligation to protect, 
guard and maintain, from initial collection to final distribution of 
research findings. It endorses key practices and operating principles 
for responsible oversight of materials collected for research and 
ensures transparency in research, fairness to research participants, 
and shared responsibility among all stakeholders involved in the 
research.[25] According to the SA MTA,[7] donors remain owners of 
their materials. This is in line with the Regulations 180 (section 7) on 
the ‘General control of human bodies, tissues, blood, blood products 
and gametes’,[37] which suggests that a donor’s rights in his/her HBMs 
are not completely relinquished when HBMs are donated. The same 
Regulations make provision for the acquisition of exclusive rights in 
deceased bodies or human tissue, blood or gametes (donated in terms 
of the NHA and any of the regulations) by a person upon receipt 
of such bodies and tissue (section 26), provided that these bodies 
or tissue are used for the purposes for which they were donated. 
Although the purpose of a tissue donation need not be expressly 
stated, tissue may only be donated for the specific outlined purposes 
in the Regulations. Consequently, a tissue donor retains proprietary 
control over the directed donation in the sense that his/her tissue may 
not be used for other than the prescribed purposes. ‘Exclusive rights’ 
in this sense should hence not be equated with ownership per se. SA 
and African communities attach great importance to their blood and 
blood products.[10,38] In accordance with our current ethicoregulatory 
framework, donors therefore retain certain controls over the use 
of their materials, even after informed consent has been obtained 
for their use. Donors can request the deletion or destruction of the 
data/HBMs and can withdraw from a research project or object 
to their materials being used, which all underscores the fact that 
the donors’ ownership rights in their materials are not completely 
relinquished and that donorship for specific purposes in itself is not 
an unconditional contribution. This is also in accordance with the 
provisions of Condition 8 of POPI (section 23-25).[14]
Benefits and benefit sharing
Examples of benefits are provided in the SA MTA[7] (clause 2.2) and 
include (but are not limited to) the sharing of information, use of 
research results, publication rights, the transfer of technology, and 
capacity building. It also provides for local researchers to benefit from 
joint publications by stipulating that publications need to be in line 
with internationally accepted ethical norms (clause 14). Historically, 
local research participants and local researchers received few to no 
benefits in exchange for their contributions to scientific discovery.[9] 
While the SA MTA includes benefit sharing as a principle, it does not 
prescribe what the benefit should entail, or that benefit sharing must 
take place. It does, however, state that this should be discussed and 
negotiated prior to transfer.
Secondary uses
The SA MTA[7] (clause 2.17) defines secondary uses as ‘the use 
of the Materials for health research purposes other than the uses 
determined in the approved protocol’. The justification for the 
approval of secondary uses by an HREC is that as secondary uses of 
materials are included in ‘health research’ as contemplated by section 
1 of the NHA, and as all HRECs are required to review and approve 
all health research proposals and protocols, approval for secondary 
uses of material must be obtained from an HREC. Clause 10.3 of 
the SA MTA states that ‘[t]he Provider must submit the informed 
consent form for Secondary Uses of the Material to the HREC should 
the need arise for Secondary Use’. This is specific to secondary uses 
related to the research project for which the materials will be used in 
accordance with the conditions stipulated in the MTA. This clause 
does not include the secondary use of materials into perpetuity. In 
addition, if it is impracticable or impossible to obtain re-consent 
from the donor, the HREC will make a considered determination 
and review and approve all secondary uses as indicated in clause 6 
of the MTA.
Dispute settlement
That disputes arise during the course of and even after a research 
project has been finalised/terminated/completed is a reality. The 
processes with regard to dispute settlement in the SA MTA are 
multilayered, consisting of informal and then more formal processes. 
As a last resort, an action may be instituted in an SA court, unless the 
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dispute is agreed by the parties to be resolved by arbitration in terms 
of a separate arbitration agreement (clause 11). Should any dispute 
arise and the jurisdiction be outside SA, local researchers, donors 
and institutions may not be able to afford to attend the proceedings. 
This requirement is also in keeping with standards prescribed by 
Western counterparts; e.g. in terms of its dispute resolution processes, 
UK Biobank specifically outlines that any unresolved dispute is to be 
mediated at the London Court of International Arbitration and that 
the language used will be English.[39] It may be argued that arbitration 
proceedings weaken the dispute resolution process somewhat, in 
that such an arbitration process may occur outside SA. However, the 
parties must agree to an arbitration process being instituted. Should 
an agreement on this issue not be reached, an action may be instituted 
in an SA court.
Conclusions
The SA MTA, like most legal documents, is not perfect, but it does 
provide a framework that can serve as a safeguard for cross-border 
transfer of HBMs in the absence of chapter 8 regulations in this 
regard. Justice and fairness, two key ethical principles in research, are 
reinforced by the SA MTA. Furthermore, the SA MTA’s provisions 
are entrenched in the fundamental principle of human dignity, a 
principle integral to health research ethics. SA is well known for 
taking the lead in protecting participants in research.[40] The SA MTA 
is a fitting example of such a safeguard.
Declaration. None.
Acknowledgements. None
Author contributions. Equal co-authors: ML, AD, SM; editing and input: 
KB, AN, KM, PC-J, AO, NM, CP.
Funding. None.
Conflicts of interest. None.
1. World Medical Association. Declaration of Taipei on Ethical Considerations Regarding Health 
Databases and Biobanks. WMA, 2016. https://www.wma.net/policies-post/wma-declaration-of-
taipei-on-ethical-considerations-regarding-health-databases-and-biobanks/ (accessed 27 October 
2018).
2. South Africa. National Health Act 61 of 2003. https://www.gov.za/documents/national-health-act 
(accessed 8 March 2019).
3. South Africa. National Health Act 61 of 20013. Regulations: Import and export of human tissue, blood, 
blood products, cultured cells, stem cells, embryos, fetal tissue, zygotes and gametes. Government 
Gazette No. 35099, March 2012. Published under Government Notice R181. https://www.gov.
za/documents/national-health-act-regulations-import-and-export-human-tissue-blood-blood-
products-0 (accessed 8 March 2019).
4. University of the Witwatersrand. The Human Research Ethics Committee Medical: Material Transfer 
Agreement for Human Biological Materials. 2018. https://www.wits.ac.za/media/wits-university/
research/documents/Wits%20MTA%202018.docx (accessed 22 January 2019).
5. Health Professions Council of South Africa. Guidelines for Good Practice in Health Care Professions: 
General Ethical Guideline for Health Researchers. HPCSA, 2016 (Booklet 13). https://www.hpcsa.
co.za/Uploads/editor/UserFiles/downloads/conduct_ethics/Booklet%2010.pdf (accessed 27 October 
2018).
6. National Department of Health, South Africa. Ethics in Health Research: Principles, Processes and 
Structures. 2nd ed. 2015. https://www.commerce.uct.ac.za/Downloads/Ethics%20in%20Health%20
Research%20Final%20A%20used.pdf (accessed 27 October 2018).
7. South Africa. National Health Act 61 of 2003. Material Transfer Agreement of Human Biological 
Materials. Government Gazette No. 41781: 719, 20 July 2018. https://www.gov.za/sites/default/
files/41781_gon719.pdf (accessed 27 October 2018).
8. Bennett AB, Streitz WD, Gacel RA. Specific issues with material transfer agreements. In: Krattiger 
A, Mahoney RT, Nelsen L, et al., eds. Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices. MIHR (Centre for the Management of Intellectual Property 
in Health Research and Development), PIPRA (Public Intellectual Property Resource for Agriculture), 
Oswaldo Cruz Foundation, and bioDevelopments-International Institute, 2007: Section 7: 697-717. 
http://www.iphandbook.org/handbook/resources/Publications/links/ipHandbook%20Volume%202.
pdf (accessed 10 October 2018).
9. Sathar A, Dhai A, van der Linde S. Collaborative international research: Ethical and regulatory issues 
pertaining to human biological materials at a South African institutional research ethics committee. 
Dev World Bioeth 2013;14(3):150-157. https://doi.org/10.1111/dewb.12018
10. Moodley K, Sibanda N, February K, Rossouw T. ‘It’s my blood’: Ethical complexities in the use, storage 
and export of biological samples: Perspectives from South African research participants. BMC Med 
Ethics 2014;15:4. https://doi.org/10.1186/1472-6939-15-4
11. Moodley K, Singh S. ‘It’s all about trust’: Reflections of researchers on the complexity and controversy 
surrounding biobanking in South Africa. BMC Med Ethics 2016;7:57. https://doi.org/10.1186/s12910-
016-0140-2
12. Mahomed S, Behrens K, Slabbert M, Sanne I. Managing human tissue transfer across national 
boundaries – an approach from an institution in South Africa. Dev World Bioeth 2016;16(1):29-35. 
https://doi.org/10.1111/dewb.12080
13. Nienaber A. Consent to and authorization of the export and use of human biological specimens for 
future research – perspectives from three African countries. Comparative and International Law 
Journal of Southern Africa 2011;44(2):225-254. https://www.jstor.org/stable/23253098 (accessed 
22  January 2019).
14. South Africa. Protection of Personal Information Act 4 of 2013. http://www.justice.gov.za/inforeg/
docs/InfoRegSA-POPIA-act2013-004.pdf (accessed 30 October 2018).
15. Bubela T, Guebert J, Mishra A. Use and misuse of material transfer agreements: Lessons in 
proportionality from research, repositories, and litigation. PLoS Biol 2015;13(2):e1002060. https://doi.
org/10.1371/journal.pbio.1002060
16. Caulfield T, Harmon SH, Joly Y. Open science versus commercialization: A modern research conflict? 
Genome Med 2012;4(2):17. https://doi.org/10.1186/gm316
17. Council for International Association of Medical Scientists. International Guidelines for Health-related 
Research Involving Humans. Geneva: CIOMS, 2016. https://cioms.ch/wp-content/uploads/2017/01/
WEB-CIOMS-EthicalGuidelines.pdf (accessed 30 October 2018).
18. Workmen’s Compensation Commissioner v De Villiers 1949 1SA 474 (C).
19. Neethling J, Potgieter JM, Visser, JM. Law of Delict. 7th paperback E-edition. Durban: LexisNexis 
South Africa, 2014:69-70 and 158-159.
20. Beckmann J. University research ethics clearances: Safety nets, or a false sense of legal immunity? S Afr 
J High Educ 2017;31(3):6. https://doi.org/10.20853/31-3-1049
21. Weiss v. Solomon. [1989] A.Q. 312 (Sup. Ct.).
22. (A11/2014) [2014] ZAWCHC 157 (22 October 2014). http://www.saflii.org/za/cases/ZAWCHC/ 
2014/157 (accessed 22 January 2019).
23. World Health Organization. Draft R&D Blueprint MTA tool text, clauses 7 - 9. WHO, 2017. http://
www.who.int/blueprint/what/norms-standards/Draft-mta-tool.pdf?ua=1 (accessed 24 October 2018).
24. Medical Research Council, UK. Ethics series: Human tissue and biological samples for use in research: 
Operational and ethical guidelines: Ownership, custodianship and the gift relationship. London: 
MRC, 2015:8-9. http://www.mrc.ac.uk/research/facilities/regulatory-support-centre/human-tissue/ 
(accessed 12 November 2018)
25. Yassin R, Lockhart N, del-Riego MG, et al. Custodianship as an ethical framework for biospecimen-
based research. Cancer Epidemiol Biomarkers Prev 2010;19(4):1012-1015. https://doi.
org/10.1158/1055-9965.EPI-10-0029
26. Verlinden M, Nys H, Ectors N, Huys I. Qualitative study on custodianship of human biological 
materials and data stored in biobanks. BMC Med Ethics 2016;17:15. https://doi.org/10.1186/s12910-
016-0098-0
27. Mahomed S. An ethico-legal framework for biobank research. UNISA College of Law, November 
2018. http://www.sahivsoc2018.co.za/wp-content/uploads/2018/11/20B_Safia-Mahomed.pdf (accessed 
8 March 2019).
28. Washington University v Catalona 490 F 3d 667 – Court of Appeals, 8th Circuit 2007. https://
openjurist.org/490/f3d/667/washington-university-v-j-catalona-md (accessed 22 January 2019).
29. Gibson SF. Washington University v Catalona: Determining ownership of genetic samples. Jurimetrics 
J 2008;48(2):167-191. https://www.jstor.org/stable/25767397?seq=1#metadata_info_tab_contents 
(accessed 22 January 2019).
30. Moore v Regents of the University of California 51 Cal. 3d 120;271 Cal. Rptr. 146; 793 P 2d 479. 
https://www.courtlistener.com/opinion/2608931/moore-v-regents-of-university-of-california/ (accessed 
22 Janu ary 2019).
31. Baulig LT. Are there property rights in human tissue? J Lancaster Gen Hosp 2010;5(3):87-90. http://
www.jlgh.org/Past-Issues/Volume-5---Issue-3/Medico-Legal-Matters.aspx (accessed 22 January 2019).
32. Harmon A. Indian tribe wins fight to limit research of its DNA. New York Times, 22 April 2010. http://
archive.boston.com/news/education/k_12/articles/2010/04/22/arizona_state_settles_dna_case_with_
tribe/ (accessed 4 November 2018) (accessed 22 January 2019).
33. Piljak Estate v. Abraham, 2014 Ontario Superior Court of Justice 2893 (CanLII). http://www.biodiritto.
org/index.php/item/download/426_6b9a9df2b3ef17ffdfc4acae0c9de4e8 (accessed 22 January 2019).
34. Yearworth v North Bristol NHS Trust 2010 Queen’s Bench. https://swarb.co.uk/yearworth-and-others-
v-north-bristol-nhs-trust-ca-4-feb-2009/ (accessed 22 January 2019).
35. Troug RD, Kesselheim AS, Joffe S. Paying patients for their tissue: The legacy of Henrietta Lacks. 
Science 2012;337(6):37-38. https://moodle.epfl.ch/pluginfile.php/1479571/mod_folder/content/0/
Paying_Patients_for_Their_Tissue-The_Legacy_of_Henrietta_Lacks_Science-2012-Truog.
pdf?forcedownload=1 (accessed 22 January 2019).
36. Mahomed S, Nöthling-Slabbert M, Pepper MS. Ownership and human tissue – the legal conundrum: 
A response to Jordaan’s critique. S Afr Med J 2017;107(3):196-198. https://doi.org/10.7196/SAMJ.2017.
v107i3.12062
37. South Africa. National Health Act 61 of 2003. Regulations: General control of human bodies, tissues, 
blood, blood products and gametes. Government Gazette No. 35099, March 2012. Published under 
Government Notice R180. http://www.samed.org.za/Filemanager/userfiles/REGULATIONS%20
REGARDING%20THE%20GENERAL%20CONTROL%20OF%20HUMAN%20BODIES%20
TISSUE%20BLOOD....pdf (accessed 8 March 2019).
38. Ojamaa B. Return our boys’ foreskins and pay, NGO told after ‘secret’ cut. 2018. https://www.the-
star.co.ke/news/2018/07/21/return-our-boys-foreskin-and-pay-ngo-told-after-secret-cut_c1790189 
(accessed 12 November 2018).
39. UK Biobank. Collaborator’s MTA v1.3, 2017. http://www.ukbiobank.ac.uk/wp-content/
uploads/2011/03/20170519-Collaborator-MTA-for-website.pdf (accessed 12 November 2018).
40. Dhai A. The evolution of research participant protections in South Africa. S Afr Med J 2017;107(7):571-
572. https://doi.org/10.7196/SAMJ.2017.v107i7.12438
Accepted 23 January 2019.
